Avenzo Goes Public: $215 Million Merger with Rallybio to Fight Cancer
Rallybio merges with Avenzo to boost cancer drug development; new AVZO company gets $215M funding and Nasdaq listing.
/ 2 items
Rallybio merges with Avenzo to boost cancer drug development; new AVZO company gets $215M funding and Nasdaq listing.
Rallybio announces a reverse merger with Candid Therapeutics, forming a new Nasdaq-listed company focused on T-cell therapies for autoimmune diseases, backed by over $500M in funding through 2030.